Answers are grounded in this paper and cite their sources.
Rates of GCIP atrophy in patients with RRMS vary according to DMT utilization. Our findings support OCT for monitoring neurodegenerative treatment effects in the retina, an easily accessible tissue, and as a practical outcome measure in RRMS clinical trials.
No takes yet. Share an insight, caveat, or question.
Button et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: